Astellas Pharma And Pfizer Announced FDA Approval Of Supplemental Marketing Application For Xtandi (Enzalutamide) For Nonmetastatic Castration-sensitive Prostate Cancer With Biochemical Recurrence At High Risk For Metastasis
Portfolio Pulse from Benzinga Newsdesk
Astellas Pharma and Pfizer have received FDA approval for a supplemental marketing application for Xtandi (enzalutamide) to treat nonmetastatic castration-sensitive prostate cancer with a high risk of metastasis after biochemical recurrence.
November 17, 2023 | 8:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Astellas Pharma's stock may see a positive impact due to the FDA approval of Xtandi for an expanded treatment indication.
The FDA approval of Xtandi for a broader indication can lead to increased sales and market penetration, positively affecting Astellas Pharma's financial performance and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Pfizer, as a partner in the marketing of Xtandi, is likely to experience a favorable short-term impact on its stock due to the expanded treatment approval by the FDA.
Pfizer's collaboration on Xtandi and the recent FDA approval for a new indication may lead to increased revenue from the drug, which is positive for the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 65
RELEVANCE 70